Shares of Larimar Therapeutics, Inc. (LRMR) are slipping nearly 14% on Tuesday morning. The clinical-stage biotechnology company focused on rare diseases reported positive data from early stage study of CTI-1601 as a treatment for Friedreich's Ataxia.
LRMR is currently trading at $11.29, down $1.83 or 13.95%, on the Nasdaq.
Friedreich ataxia is a rare inherited disease caused by patients' inability to produce sufficient amounts of a protein called frataxin. This disorder is characterized by difficulty walking and poor balance, slowness and slurring of speech, a loss of sensation in the arms and legs, and heart palpitations and shortness of breath.
The company said study data demonstrate proof-of-concept by showing that daily subcutaneous injections of CTI-1601 for up to 13 days resulted in dose-dependent increases in frataxin levels from baseline compared to placebo in all evaluated tissues.
Safety data indicate that repeated subcutaneous injections of CTI-1601 were generally well tolerated at doses up to 100 mg administered daily for 13 days.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.